A new tool to monitor bladder cancer is four
times more effective than the conventional laboratory test in detection of the disease. According to the January
edition of the Journal of American Medical Association, researchers led by The University of Texas M.D. Anderson Cancer
Center, at 23 clinical sites, enrolled 668 patients with a history of bladder cancer, to look at how NMP22 assay effects
the detection of recurrences. It in now apparent that the NMP22 assay detected 49.5 percent of recurrences (51 out of
103) when urine cytology detection was only 12.2 percent (12 out of 98). When combined with cystoscopy NMP22
assay detected 99 percent of bladder cancers and an improvement of 8 percent when using cystoscopy alone.%uFFFD Bladder
cancer is the 5th most common cancer in the United States, and the possibility of it recurring is as high as 50 percent.
These improvements in detection will help prevent the advancement of the bladder cancer before it requires aggressive
treatment.Note: The contents of this blog are for informational purposes only and should not be construed as medical advice or substitute for professional care. For medical emergencies, dial 911!
Improvements for recurrent bladder cancer
A new tool to monitor bladder cancer is four
times more effective than the conventional laboratory test in detection of the disease. According to the January
edition of the Journal of American Medical Association, researchers led by The University of Texas M.D. Anderson Cancer
Center, at 23 clinical sites, enrolled 668 patients with a history of bladder cancer, to look at how NMP22 assay effects
the detection of recurrences. It in now apparent that the NMP22 assay detected 49.5 percent of recurrences (51 out of
103) when urine cytology detection was only 12.2 percent (12 out of 98). When combined with cystoscopy NMP22
assay detected 99 percent of bladder cancers and an improvement of 8 percent when using cystoscopy alone.%uFFFD Bladder
cancer is the 5th most common cancer in the United States, and the possibility of it recurring is as high as 50 percent.
These improvements in detection will help prevent the advancement of the bladder cancer before it requires aggressive
treatment.
